乳腺浸润性导管癌性激素受体与耐药因子的相关性研究  

The correlation of sex hormone receptor and drug resistance factor in infiltrating ductal carcinoma of breast

作　　者：郭莉莉[1] 仝铁[2] 胡庆[3] 

机构地区：[1]贵阳中医学院第二附属医院病理科,550003 [2]贵阳市妇幼保健院病理科,550003 [3]贵阳市妇幼保健院预防保健科

出　　处：《贵州医药》2010年第6期493-496,共4页Guizhou Medical Journal

摘　　要：目的探讨非特殊性乳腺浸润性导管癌雌、孕激素受体(ER、PR)、癌基因(cerbB-2)表达与常用化疗药物耐药因子的相关性及其临床意义。方法应用免疫组织化学方法观察65例乳腺浸润性导管癌性激素受体ER、PR、CerbB-2及耐药因子P-糖蛋白(P-gp)、谷胱甘肽-S-转移酶-π(GST-π)、DNA拓扑异构酶Ⅱ(TOPOⅡ)表达,并进一步对不同治疗前提分组中各耐药因子表达进行比较分析。结果患者大都存在多药耐药现象(81.6%),耐药情况与肿瘤分化程度无关,与是否绝经无关,但与癌肿的临床分期有关;不同治疗前提分组中ER(-),CerbB-2低表达组TOPOⅡ的表达与其它组比较差异有统计学意义(P<0.05)。结论联合检测乳腺浸润性导管癌组织中ER、CerbB-2和耐药因子TOPOⅡ的表达,对乳腺浸润性导管癌治疗方案的制定和预后判断有重要的参考价值。Objective To investigate correlation and clinical significantce of theexpression of ER, PR, CerbB-2 and multiple drug resistance gene in infiltratingductal carcinoma of breast. Methods Sixtyfive cases with infiltrating ductal carcinoma of breast were detected by immunohistochemical method for ER, PR, CerbB-2, P-gp, GST-π, and TOPO Ⅱ , and expression of multiple drug resistance gene were analyzed in various groups. Results The positive expression rate of drug resistance was 81. 6 %, which was related to clinical stage but no related to differentiation and menopause. Expression of TOPO Ⅱ has significant difference in the negative expressions of ER and CerbB-2 to compare other groups. Conclusion The expression of ER, CerbB-2 and TOPOⅡ in breast carcinoma tissues has an instructive significance for leading clinical therapy and predicting prognostic of patients with infiltra- ting ductal carcinoma of breast.

关 键 词：乳腺浸润性导管癌 性激素受体 多药耐药 

分 类 号：R737.9[医药卫生—肿瘤]